Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951005 | 1.00 | IDO1 (0.47) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL6243496 | 0.82 | IDO1 (0.46) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL28862765 | 0.79 | IDO1 (0.44) | IDO1MAPTL3MBTL1KDM4EGAA | |
| SCHEMBL31244592 | 0.74 | PARP1 (0.40) | MAPTL3MBTL1KDM4EGAAGSK3B | |
| SCHEMBL29955806 | 0.74 | CACNB4 (0.41) | GAA | |
| SCHEMBL29954649 | 0.74 | TP53 (0.46) | MAPTALDH1A1TP53SMN1; SMN2EGFR | |
| SCHEMBL29952427 | 0.74 | EPHX2 (0.40) | MAPTKDM4EGAAALDH1A1MEN1 | |
| SCHEMBL29956773 | 0.74 | GAA (0.39) | MAPTKDM4EGAACREBBPALDH1A1 | |
| SCHEMBL29953205 | 0.74 | PGR (0.43) | IDO1MAPTTDO2MEN1TP53 | |
| SCHEMBL1314441 | 0.74 | HTR7 (0.40) | MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160331725-A1 | USE OF COMPOUNDS THAT ARE ABLE TO INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASE STATES ASSOCIATED WITH A REDUCED IGF-1 SERUM LEVEL IN HUMANS AND ANIMALS | VEIJLEN N.V. | 2016-11-17 | — | — | US | claimed |
| JP-4641942-B2 | — | — | 2011-03-02 | — | — | JP | claimed |
| US-20080194553-A1 | compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition,in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome | VEIJLEN N.V. (NL) | 2008-08-14 | — | — | US | claimed |
| EP-1670444-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | Veijlen N.V. (AN) | 2006-06-21 | — | — | EP | claimed |
| WO-2005039546-A2 | USE OF INDOLEACETIC ACID DERIVATIVES WHICH INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASES | VEIJLEN N.V. (AN) | 2005-05-06 | — | — | WO | claimed |
| CN-111801097-A | Semi-synthetic aurone and method of use thereof | 肯塔基大学研究基金会 | 2020-10-20 | — | — | CN | disclosed |
| US-10716778-B2 | Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals | Veijlen (CW) | 2020-07-21 | — | — | US | disclosed |
| US-20160331725-A1 | USE OF COMPOUNDS THAT ARE ABLE TO INCREASE THE SERUM IGF-1 LEVEL FOR THE PREPARATION OF A THERAPEUTICAL COMPOSITION FOR TREATMENT OF VARIOUS DISEASE STATES ASSOCIATED WITH A REDUCED IGF-1 SERUM LEVEL IN HUMANS AND ANIMALS | VEIJLEN N.V. | 2016-11-17 | — | — | US | disclosed |
| US-9408405-B2 | Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals | VEIJLEN N.V. (CW) | 2016-08-09 | — | — | US | disclosed |
| US-20150038544-A1 | ANIMAL FEED COMPOSITION | VEIJLEN N.V. (AN) | 2015-02-05 | — | — | US | disclosed |
| US-8883233-B2 | Animal feed composition | VEIJLEN N.V. (AN) | 2014-11-11 | — | — | US | disclosed |
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-4383089-A | Process for the production of polyepoxy silicate resin | BLOUNT DAVID H | 1983-05-10 | — | — | US | disclosed |
| US-4383049-A | POLYURETHANES | BLOUNT DAVID H | 1983-05-10 | — | — | US | disclosed |
| US-4377646-A | REACTING AN EPOXY COMPOUND, SILICIC ACID, AND A POLYISOCYANATE USING A LEWIS ACID CATALYST; POLYURETHANES; INSULATION | BLOUNT DAVID H | 1983-03-22 | — | — | US | disclosed |
| US-4376173-A | LIGNIN, CELLULOSE, POLYURETHANE FOAM, POLYISOCYANATE | BLOUNT DAVID H | 1983-03-08 | — | — | US | disclosed |
| US-4367326-A | Process for the production of polyepoxy silicate resins | DORSEY & WHITNEY LLP | 1983-01-04 | — | — | US | disclosed |
| US-4357463-A | HEATING A SILICON COMPOUND, AN EPOXIDE, A DICARBOXYLIC ACID OR ANHYDRIDE, AND A LEWIS ACID; COATINGS; MOLDING MATERIALS; ADHESIVES | BLOUNT DAVID H | 1982-11-02 | — | — | US | disclosed |
| US-3975196-A | Photoconductive charge transfer complex for electrophotography | PITNEY-BOWES, INC. (US) | 1976-08-17 | — | — | US | disclosed |
| US-3923996-A | 3-Substituted-oxindoles in compositions and methods of treating obesity | SANDOZ AG | 1975-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | IDO1 3938/4885MAPT 1883/4885L3MBTL1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.